169 related articles for article (PubMed ID: 10946349)
21. BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer.
Schubert EL; Mefford HC; Dann JL; Argonza RH; Hull J; King MC
Genet Test; 1997; 1(1):41-6. PubMed ID: 10464624
[TBL] [Abstract][Full Text] [Related]
22. An unaffected individual from a breast/ovarian cancer family with germline mutations in both BRCA1 and BRCA2.
Moslehi R; Russo D; Phelan C; Jack E; Antman K; Narod S
Clin Genet; 2000 Jan; 57(1):70-3. PubMed ID: 10733239
[TBL] [Abstract][Full Text] [Related]
23. Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families.
Vaziri SA; Krumroy LM; Rostai M; Casey G
Hum Mutat; 2001; 17(1):74. PubMed ID: 11139249
[TBL] [Abstract][Full Text] [Related]
24. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
Burke W; Daly M; Garber J; Botkin J; Kahn MJ; Lynch P; McTiernan A; Offit K; Perlman J; Petersen G; Thomson E; Varricchio C
JAMA; 1997 Mar; 277(12):997-1003. PubMed ID: 9091675
[TBL] [Abstract][Full Text] [Related]
25. Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information.
DiCastro M; Frydman M; Friedman I; Shiri-Sverdlov R; Papa MZ; Goldman B; Friedman E
Am J Med Genet; 2002 Aug; 111(2):147-51. PubMed ID: 12210341
[TBL] [Abstract][Full Text] [Related]
26. Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses.
Bluman LG; Rimer BK; Regan Sterba K; Lancaster J; Clark S; Borstelmann N; Iglehart JD; Winer EP
Psychooncology; 2003; 12(5):410-27. PubMed ID: 12833555
[TBL] [Abstract][Full Text] [Related]
27. The majority of 22 Dutch high-risk breast cancer families are due to either BRCA1 or BRCA2.
Peelen T; Cornelis RS; van Vliet M; Petrij-Bosch A; Cleton-Jansen AM; Meijers-Heijboer H; Klijn JG; Vasen HF; Cornelisse CJ; Devilee P
Eur J Hum Genet; 1996; 4(4):225-30. PubMed ID: 8875189
[TBL] [Abstract][Full Text] [Related]
28. BRCA1 and BRCA2 mutations among Finnish ovarian carcinoma families.
Sarantaus L; Auranen A; Nevanlinna H
Int J Oncol; 2001 Apr; 18(4):831-5. PubMed ID: 11251181
[TBL] [Abstract][Full Text] [Related]
29. Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families.
Ikeda N; Miyoshi Y; Yoneda K; Shiba E; Sekihara Y; Kinoshita M; Noguchi S
Int J Cancer; 2001 Jan; 91(1):83-8. PubMed ID: 11149425
[TBL] [Abstract][Full Text] [Related]
30. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
31. Marker segregation information in breast/ovarian cancer genetic counseling: is it still useful? Groupe Génétique et Cancer de la Fédération Nationale des Centres de Lutte Contre le Cancer.
Essioux L; Girodet C; Sinilnikova O; Pagès S; Eisinger F; de Résende S; Maugard C; Lanoë D; Longy M; Bignon YJ; Sobol H; Bonaïti-Pellié C; Stoppa-Lyonnet D
Am J Med Genet; 1998 Sep; 79(3):175-83. PubMed ID: 9788557
[TBL] [Abstract][Full Text] [Related]
32. Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2.
Berchuck A; Carney M; Lancaster JM; Marks J; Futreal AP
Clin Obstet Gynecol; 1998 Mar; 41(1):157-66. PubMed ID: 9504233
[No Abstract] [Full Text] [Related]
33. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer EJ; Verhoog LC; Brekelmans CT; Seynaeve C; Tilanus-Linthorst MM; Wagner A; Dukel L; Devilee P; van den Ouweland AM; van Geel AN; Klijn JG
Lancet; 2000 Jun; 355(9220):2015-20. PubMed ID: 10885351
[TBL] [Abstract][Full Text] [Related]
34. Detection of BRCA1 and BRCA2 mutations in breast cancer families by a comprehensive two-stage screening procedure.
Spitzer E; Abbaszadegan MR; Schmidt F; Hauser A; Buwitt U; Lauter FR; Pötschick K; Krocker J; Elling D; Grosse R
Int J Cancer; 2000 Feb; 85(4):474-81. PubMed ID: 10699917
[TBL] [Abstract][Full Text] [Related]
35. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families.
Vahteristo P; Eerola H; Tamminen A; Blomqvist C; Nevanlinna H
Br J Cancer; 2001 Mar; 84(5):704-8. PubMed ID: 11237395
[TBL] [Abstract][Full Text] [Related]
36. Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2.
Ligtenberg MJ; Hogervorst FB; Willems HW; Arts PJ; Brink G; Hageman S; Bosgoed EA; Van der Looij E; Rookus MA; Devilee P; Vos EM; Wigbout G; Struycken PM; Menko FH; Rutgers EJ; Hoefsloot EH; Mariman EC; Brunner HG; Van 't Veer LJ
Br J Cancer; 1999 Mar; 79(9-10):1475-8. PubMed ID: 10188893
[TBL] [Abstract][Full Text] [Related]
37. Psychosocial issues associated with genetic testing for breast and ovarian cancer risk: an integrative review.
Pasacreta JV
Cancer Invest; 2003; 21(4):588-623. PubMed ID: 14533449
[TBL] [Abstract][Full Text] [Related]
38. Overestimation of hereditary breast cancer risk.
Iglehart JD; Miron A; Rimer BK; Winer EP; Berry D; Shildkraut MJ
Ann Surg; 1998 Sep; 228(3):375-84. PubMed ID: 9742920
[TBL] [Abstract][Full Text] [Related]
39. Attitudes and distress levels in women at risk to carry a BRCA1/BRCA2 gene mutation who decline genetic testing.
Lodder L; Frets PG; Trijsburg RW; Klijn JG; Seynaeve C; Tilanus MM; Bartels CC; Meijers-Heijboer EJ; Verhoog LC; Niermeijer MF
Am J Med Genet A; 2003 Jun; 119A(3):266-72. PubMed ID: 12784290
[TBL] [Abstract][Full Text] [Related]
40. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Kuschel B; Lux MP; Goecke TO; Beckmann MW
Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
